Avirup Guha, Director of Cardio-Oncology at Georgia Cancer Center, shared a post on LinkedIn:
“How should oncology trials define CV safety events?
Marc Bonaca explains how Table 1 and Figure 1 from our AHA Scientific Statement support mechanism-guided, adjudicated endpoints.
Prior post.”
Title: Defining Cardiovascular Endpoints in Oncology Trials: Challenges and Opportunities: A Scientific Statement From the American Heart Association
Authors: Ana Barac, Avirup Guha, Thomas R. Fleming, Marc Bonaca, Paaladinesh Thavendiranathan, Anita Deswal, Laleh Amiri-Kordestani, Vishal Bhatnagar, Raul Cordoba, Sara Hurvitz, Alex A. Adjei, Neeraj Agarwal on behalf of the American Heart Association Cardio-Oncology Committee of the Council on Clinical Cardiology and Council on Genomic and Precision Medicine; Council on Cardiovascular and Stroke Nursing; and Council on Peripheral Vascular Disease
Other articles featuring Avirup Guha on OncoDaily.